Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Intangibles (2016 - 2025)

Coherus Oncology's Intangibles history spans 12 years, with the latest figure at $1.6 million for Q3 2025.

  • For Q3 2025, Intangibles fell 93.71% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $1.6 million, down 93.71%, while the annual FY2024 figure was $24.8 million, 14.11% down from the prior year.
  • Intangibles for Q3 2025 was $1.6 million at Coherus Oncology, down from $24.8 million in the prior quarter.
  • Across five years, Intangibles topped out at $28.9 million in Q4 2023 and bottomed at $1.6 million in Q3 2025.
  • The 5-year median for Intangibles is $4.7 million (2021), against an average of $10.9 million.
  • The largest annual shift saw Intangibles skyrocketed 386.58% in 2023 before it crashed 93.71% in 2025.
  • A 5-year view of Intangibles shows it stood at $3.6 million in 2021, then skyrocketed by 66.46% to $5.9 million in 2022, then soared by 386.58% to $28.9 million in 2023, then dropped by 14.11% to $24.8 million in 2024, then plummeted by 93.55% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Intangibles are $1.6 million (Q3 2025), $24.8 million (Q4 2024), and $25.5 million (Q3 2024).